NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Anand Rathi Report
Here are the 10 things to know before investing in Sai Parenterals IPO
1. Sai Parenterals Ltd. will launch its initial public offering (IPO) on March 24 and the offer closes for subscription on March 27.
2. A pharma company that makes medicines and also provides services to other pharma companies has fixed the price band in the range of Rs 372 to Rs 392 per equity share.
3. Sai Parenterals is a book-build issue of Rs 408.79-crore. The issue is a combination of fresh issue of 0.73 crore shares aggregating to Rs 285.00 crores and offer for sale of 0.32 crore shares aggregating to Rs 123.79 crores.
4. Investors can place bids starting from a minimum of 38 shares and in multiples thereafter, meaning a minimum amount of investment required by an individual investor (retail) is Rs 14,896 based on upper price.
5. Arihant Capital Markets is the book running lead manager of the issue while Bigshare Services Pvt Ltd. is the registrar to the offer.
6. Sai Life Sciences, Innova Captab, Senores Pharma and Gland Pharma are among Sai Parenterals' peers in the sector.
7. Objects of the fresh Issue:
- Capacity dxpansion and upgradation of manufacturing facilities.
- Establishment of a new research and development centre.
- Repayment, prepayment of certain outstanding borrowing.
- Working capital requirement.
- General corporate purpose.
8. Key Strategies:
- Expansion into global injectable formulations market.
- Capitalise on CDMO opportunity by leveraging our manufacturing capabilities with enhanced R&D competences.
- Strengthening its presence in Regulated Markets through the upcoming Noumed's manufacturing facility at Adelaide, Australia.
- Focus on new product development to drive future growth.
- Grow its own branded generic formulations business by leveraging opportunities in the international markets.
- Expand capabilities through strategic acquisitions.
9. Key Risk:
- Their manufacturing facilities are mainly located in Hyderabad and Ongole, so they face risks if anything goes wrong in these regions. Any issues like economic slowdown, regulatory or political changes, shutdowns, or natural disasters could negatively impact their business, operations, and financial performance.
- A large portion of their revenue comes from injectable medicines—about 44.78% in FY2025, 47.64% in FY2024, and 92.03% in FY2023. This means they are highly dependent on this segment, and if demand for injectables falls, it could negatively impact their business, financial performance, and cash flows.
- Their manufacturing facilities are regularly inspected by regulators and customers. If they fail to meet required standards, they could face regulatory action, which may harm their reputation and negatively impact their business, financial performance, and cash flows.
- They source most of their key raw materials (like APIs and other ingredients) from multiple suppliers but do not have long-term contracts with them. This creates a risk—if suppliers reduce or stop supplies, it could negatively affect their operations. Also, any increase or fluctuation in raw material prices can impact their costs, profitability, and overall financial performance.
- Their success depends on how quickly they can develop and launch new products. If they are unable to do this on time, it could negatively impact their business, performance, and financial condition.
- A significant part of their revenue comes from a limited number of customers. If they lose any of these key customers or if those customers face financial problems, it could negatively impact their business, performance, and financial condition.
- Their international operations expose them to various risks such as complex regulations, legal and tax issues, and economic uncertainties in different countries. These factors could negatively impact their business, performance, and financial condition.
- There are ongoing legal cases involving the company, its promoters, some directors, and its key subsidiary, which could create risks and potentially affect its business and reputation.
- They plan to expand and upgrade their manufacturing facilities using funds from the fresh issue, which will require temporarily stopping operations at Unit I and Unit II for about 6 months. This could impact production in the short term. They are also dependent on third-party contractors and specialists to complete this work, so any delays or issues in execution could further affect timelines and operations.
- The Indian pharmaceutical industry is highly regulated, and they must follow strict rules and standards. If they fail to comply with current or future regulations, it could negatively impact their business, operations, and financial performance.
10. Valuation and Outlook:
Sai Parenterals is valued at ~10.6x to price/sales on FY25 sales (at the upper band) is valued fairly in relation to its competitors.
Considering the company's consistent track record and superior financial metrics, the valuation is fully priced in and is rated “Subscribe-Long Term”.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
